Pharmacological approach to evaluate aerosol pulmonary deposition

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 18, Issue 2, 2005, Pages 183-192

  Girodet, Pierre Olivier ^b   Molimard, Mathieu ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NONE

Author keywords

Airways; Bioavailability; Deposition; Inhaled drugs; Lung delivery; Pharmacodynamic; Pharmacokinetic

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; TETRACOSACTIDE; TRIAMCINOLONE ACETONIDE;

AEROSOL; BRONCHODILATATION; BRONCHUS OBSTRUCTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG MEGADOSE; DRUG SCREENING; DRUG SPECIFICITY; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; HEART RATE; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; IN VIVO STUDY; LUNG DEPOSIT; LUNG SCINTISCANNING; PATIENT SELECTION; REVIEW; SIDE EFFECT; TREMOR;

EID: 21344434768     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2005.18.183     Document Type: Review

References (66)

1. Vanden Burgt, J.A., W.W. Busse, R.J. Martin, et al. 2000. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J. Allergy Clin. Immunol. 106:1209-1226.
2. Martin, R.J. 2002. Therapeutic significance of distal airway inflammation in asthma. J. Allergy Clin. Immunol. 109:S447-S460.
3. Kwong, W.T., S.L. Ho, and A.L. Coates. 2000. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J. Aerosol. Med. 13:303-314.
4. Marple, V.A., D.L. Roberts, F.J. Romay, et al. 2003. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design. J. Aerosol. Med. 16:283-299.
5. Marple, V.A., B.A. Olson, K. Santhanakrishnan, et al. 2003. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. J. Aerosol. Med. 16:301-324.
6. Borgstrom, L. 1999. In vitro, ex vivo, in vivo veritas. Allergy 54:88-92.
7. Lofdahl, G.G., L. Andersson, et al. 1997. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur. Respir. J. 10: 2474-2478.
8. Richards, J., P. Hirst, G. Pitcairn, et al. 2001. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J. Aerosol. Med. 14:197-208.
9. Nayak, A., R. Lanier, S. Weinstein, et al. 2002. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study. Chest 122:1956-1965.
10. Yanai, M., J. Hatazawa, F. Ojima, et al. 1998. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 11:1342-1348.
11. Berridge, M.S., and D.L. Heald. 1999. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J. Clin. Pharmacol. Suppl:25S-29S.
12. Anhoj, J., H. Bisgaard, and B.J. Lipworth. 1999. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br. J. Clin. Pharmacol. 47:333-336.
13. Chrystyn, H., S.A. Corlett, and V. Silkstone. 1996. Lung bioavailability of generic and innovator salbutamol MDIs. Thorax 51:658.
14. Clark, D.J., J. Gordon-Smith, G. McPhate, et al. 1996. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 51:325-326.
15. Newnham, D.M., and B.J. Lipworth. 1994. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 49:762-770.
16. Duarte, A.G., R. Dhand, R. Reid, et al. 1996. Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Am. J. Respir. Crit. Care Med. 154:1658-1663.
17. Borgstrom, L., and M. Nilsson. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm. Res. 7:1068-1070.
18. Clark, D.J., and B.J. Lipworth. 1996. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br. J. Clin. Pharmacol. 41:247-249.
19. Lipworth, B.J., and D.J. Clark. 1998. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer. Br. J. Clin. Pharmacol. 45:160-163.
20. Clark, D.J., and B.J. Lipworth. 1996. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 51:981-984.
21. Newnham, D.M., N.M. Wheeldon, B.J. Lipworth, et al. 1993. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 48: 656-658.
22. Lipworth, B.J., D.M. Newnham, R.A. Clark, et al. 1995. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 50:54-61.
23. Lipworth, B.J., and D.J. Clark. 1997. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 52:1036-1039.
24. Lipworth, B.J., and D.J. Clark. 1997. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm. Pharmacol. Ther. 10:211-214.
25. Logsdon, T.W., X. Zhou, P. Breen, et al. 1997. Determination of albuterol in plasma after aerosol inhalation by gas chromatography-mass spectrometry with selected-ion monitoring. J. Chromatogr. B Biomed. Sci. Appl. 692:472-477.
26. Joguparthi, V., P. Breen, C. Compadre, et al. 2003. Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. J. Aerosol. Med. 16:47-53.
27. Ryrfeldt, A., P. Andersson, S. Edsbacker, et al. 1982. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. Suppl. 122:86-95.
28. Harding, S.M. 1990. The human pharmacology of fluticasone propionate. Respir. Med. 84:25-29.
29. Wilson, A.M., E.J. Sims, L.C. Orr, et al. 1999. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet 354:1357-1358.
30. Dempsey, O.J., W.J. Coutie, A.M. Wilson, et al. 1999. Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax 54:614-617.
31. Pedersen, S., G. Steffensen, and S.V. Ohlsson. 1993. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br. J. Clin. Phannacol. 36:211-214.
32. Snell, N.J., and D. Ganderton. 1999. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Respir. Med. 93: 123-133.
33. Thorsson, L., S. Edsbacker, and T.B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 7:1839-1844.
34. Thorsson, L., and S. Edsbacker. 1998. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur. Respir. J. 12:1340-1345.
35. Esmailpour, N., P. Hogger, K.F. Rabe, et al. 1997. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur. Respir. J. 10:1496-1499.
36. Clarke, J.R., H. Aston, and M. Silverman. 1993. Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness. Arch. Dis. Child. 69:125-129.
37. Giannini, D., A. Di Franco, E. Bacci, et al. 2000. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction. Chest 117:1319-1323.
38. Barnes, P.J., and N.B. Pride. 1983. Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br. J. Clin. Pharmacol. 15:677-682.
39. Lipworth, B.J., and D.G. McDevitt. 1989. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J. Clin. Pharmacol. 36:239-245.
40. Fowler, S.J., and B.J. Lipworth. 2001. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. Br. J. Clin. Pharmacol. 51:359-362.
41. Woodcock, A., A. Williams, L. Batty, et al. 2002. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant. J. Aerosol. Med. 15:407-414.
42. Busse, W.W., S. Brazinsky, K. Jacobson, et al. 1999. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 104:1215-1222.
43. Leach, C. 1999. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J. Allergy Clin. Immunol. 104: S250-S252.
44. Leach, C.L., P.J. Davidson, B.E. Hasselquist, et al. 2002. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 122:510-516.
45. Finney, D.J., and H.O. Schild. 1966. Parallel line assay with successive adjustment of doses. Br. J Pharmacol 28:84-92.
46. Dahl, R., B. Lundback, J.L. Malo, et al. 1993. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 104:1352-1358.
47. Pedersen, S., and P. O'Byrne. 1997. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52:1-34.
48. Goldberg, S., T. Einot, N. Algur, et al. 2002. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer. Ann. Allergy Asthma Immunol. 89:566-571.
49. Wong, C.A., L.J. Walsh, C.J. Smith, et al. 2000. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399-1403.
50. Kelly, H.W., and H.S. Nelson. 2003. Potential adverse effects of the inhaled corticosteroids. J. Allergy Clin. Immunol. 112:469-479.
51. Brown, P.H., S.P. Matusiewicz, C. Shearing, et al. 1993. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 48:967-973.
52. Wilson, A.M., and B.J. Lipworth. 1999. Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br. J. Clin. Phannacol. 48:579-585.
53. Brutsche, M.H., I.C. Brutsche, M. Munawar, et al. 2000. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 356:556-561.
54. Brown, P.H., G. Blundell, A.P. Greening, et al. 1991. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high-dose inhaled corticosteroids. Respir. Med. 85:511-516.
55. Kirkpatrick, C., H. Buck, and S. Ellis. 2003. Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler. J. Aerosol. Med. 16:31-36.
56. Grinspoon, S.K., and B.M. Biller. 1994. Clinical review 62: laboratory assessment of adrenal insufficiency. J. Clin. Endocrinol. Metab. 79:923-931.
57. Broide, J., R. Soferman, S. Kivity, et al. 1995. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J. Clin. Endocrinol. Metab. 80:1243-1246.
58. Molimard, M., C. Raherison, S. Lignot, et al. 2003. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol. Med. 16:249-254.
59. Girodet, P.O., C. Raherison, A. Abouelfath, et al. 2003. [Real-life use of inhaler devices for chronic obstructive pulmonary disease in primary care]. Therapie 58:499-504.
60. Daley-Yates, P.T., A.C. Price, J.R. Sisson, et al. 2001. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol. 51:400-409.
61. Edsbacker, S. 1999. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 58:7-16; discussion 51-52.
62. Chaplin, M.D., W. Rooks, 2nd, E.W. Swenson, et al. 1980. Flunisolide metabolism and dynamics of a metabolite. Clin. Pharmacol. Ther. 27:402-413.
63. Chaplin, M.D., W.C. Cooper, E.J. Segre, et al. 1980. Correlation of flunisolide plasma levels to eosinopenic response in humans. J. Allergy Clin. Immunol. 65:445-453.
64. Mackie, A.E., G.P. Ventresca, R.W. Fuller, et al. 1996. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br. J. Clin. Plmrmacol. 41: 539-542.
65. Thorsson, L., K. Dahlstrom, S. Edsbacker, et al. 1997. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 43:155-161.
66. Derendorf, H., G. Hochhaus, S. Rohatagi, et al. 1995. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J. Clin. Pharmacol. 35:302-305.